Showing 5,041 - 5,060 results of 5,673 for search 'Paduli~', query time: 3.40s Refine Results
  1. 5041
  2. 5042
  3. 5043
  4. 5044

    Safety, Tolerability, and Immunogenicity of the Invaplex<sub>AR-Detox</sub> <i>Shigella</i> Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial by Geert V. T. Roozen, Nsofwa Sukwa, Masuzyo Chirwa, Jessica A. White, Marcus Estrada, Nicole Maier, Kevin R. Turbyfill, Renee M. Laird, Akamol E. Suvarnapunya, Aicha Sayeh, Flavia D’Alessio, Candice Marion, Laura Pattacini, Marie-Astrid Hoogerwerf, Rajagopal Murugan, Manuela Terrinoni, Jan R. Holmgren, Sodiomon B. Sirima, Sophie Houard, Michelo Simuyandi, Meta Roestenberg

    Published 2025-01-01
    “…This article describes the protocol of a study that will be the first to assess the safety, tolerability, and immunogenicity of Invaplex<sub>AR-Detox</sub> co-administered with dmLT in healthy adults in low-endemic and high-endemic settings. Methods: In a multi-center, randomized, double-blind, and placebo-controlled dose-escalation phase Ia/b trial, the safety, tolerability, and immunogenicity of three intramuscular vaccinations administered 4 weeks apart with 2.5 µg or 10 µg of Invaplex<sub>AR-Detox</sub> vaccine, alone or in combination with 0.1 µg of the dmLT adjuvant, will first be assessed in a total of 50 healthy Dutch adults (phase Ia) and subsequently in 35 healthy Zambian adults (phase Ib) aged 18–50 years. …”
    Get full text
    Article
  5. 5045
  6. 5046
  7. 5047
  8. 5048
  9. 5049
  10. 5050
  11. 5051

    CRSI handbook, based upon the 1971 ACI building code /

    Published 1972
    View in OPAC
    Book
  12. 5052
  13. 5053

    Respiratory syncytial virus vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Association of General and Family Medicine, the Portuguese Society of Cardiology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Endocrinology, Diabetes and Metabolism, and the Portuguese Society of Internal Medicine by Tiago Alfaro, Filipe Froes, Cláudia Vicente, Rui Costa, Cristina Gavina, Rui Baptista, António Maio, Saraiva da Cunha, João Sérgio Neves, Pedro Leuschner, Sofia Duque, Paula Pinto

    Published 2025-12-01
    “…Background Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract infection, hospitalisation and death in adults.Methods Based on evidence regarding the impact of RSV on adult populations at risk for severe infection and the efficacy and safety of RSV vaccines, the Portuguese Society of Pulmonology, the Portuguese Association of General and Family Medicine, the Portuguese Society of Cardiology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Endocrinology, Diabetes and Metabolism, and the Portuguese Society of Internal Medicine endorses this position paper with recommendations to prevent RSV-associated disease and its complications in adults through vaccination.Conclusion The RSV vaccine is recommended for people aged ≥50 years with risk factors (chronic obstructive pulmonary disease, asthma, heart failure, coronary artery disease, diabetes, chronic kidney disease, chronic liver disease, immunocompromise, frailty, dementia, and residence in a nursing home) and all persons aged ≥60 years. …”
    Get full text
    Article
  14. 5054
  15. 5055
  16. 5056
  17. 5057
  18. 5058
  19. 5059
  20. 5060